Introduction: Patients with multiple sclerosis (MS) generally undergo long-term treatment with disease-modifying therapies (DMTs). In the US, patients taking glatiramer acetate, interferon beta-1a, or interferon beta-1b, typically use a mechanical autoinjector. Recent
BETACONNECT was demonstrated and patients performed simulated injections with BETACONNECT before rating it across the same attributes.
Patient overall autoinjector preference was assessed.
Results: Ninety patients completed the survey: 63 were using autoinjectors for Copaxone, 25
for Rebif, and 2 for Extavia. BETACONNECT scored higher than mechanical autoinjectors across all 18 attributes. The top attributes of an ideal autoinjector were the injection process is Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/B7D 4F0602A357686.
Electronic supplementary material The online version of this article (doi:10.1007/s40120-016-0047-3) contains supplementary material, which is available to authorized users. easy overall, easy to push the button to start the injection, and autoinjector is comfortable to hold during injections. Unique BETACONNECT features most valued by patients were the built-in dwell time, self-check function, greater ability to customize injections, adjustment of injection speed, low injection noise, and automatic needle retraction. Overall, 75 out of 90 patients (83%) expressed a preference for BETACONNECT over their current autoinjector.
Conclusion: BETACONNECT attributes and features were highly rated by patients, compared with both an ideal autoinjector and their current mechanical autoinjectors. These findings suggest that the use of BETACONNECT may increase patient satisfaction and potentially increase overall medication adherence.
INTRODUCTION
Multiple sclerosis (MS) is a chronic autoimmune disease that can affect all parts of the central nervous system. Most patients experience periods of neurological relapses and remissions early in their disease course, followed by progressive neurological deterioration [1] . There are no curative treatments for MS, but disease-modifying therapies (DMTs) such as interferon beta-1b are considered effective therapies for the management of MS [2] .
Long-term management with DMTs can alter the pathological immune responses associated with MS, prevent relapses, and reduce the risk of disease progression [3] . Optimal management of MS with DMTs depends on a number of factors, including starting the treatment early and adherence to the medication regimen [2, 4] . Nevertheless, poor adherence to DMTs is frequently seen among patients with MS [4] and can lead to increased risk of relapse and higher medical costs [5, 6] .
Several
DMTs are given as patient-administered injections via the use of an autoinjector, as these devices can reduce patients' anxiety about self-administered injections and contribute to a lower rate of injection site reactions [7] [8] [9] . Moreover, autoinjector use may be associated with improved adherence to injectable therapy [10] . [12] .
The objective of the current survey was to use a comprehensive survey-based approach to assess patient perceptions of BETACONNECT in comparison with their experiences using mechanical autoinjectors that are available in the US. This survey builds upon results from recently published surveys which have shown high levels of satisfaction with BETACONNECT and preference over previous methods for injecting interferon beta-1b therapy [13, 14] .
The current survey is the first to compare BETACONNECT with mechanical autoinjectors. Figure 1 shows the BETACONNECT autoinjector. Note that the Rebismart Ò autoinjector (Merck Serono) was not included as it has not been approved for use in the US, and we also excluded those using the Rebidose Ò 
METHODS

Autoinjectors
Participants
Recruitment of patients for this survey was organized through an independent external Fig. 1 The BETACONNECT autoinjector. Comparator autoinjectors images and details are available from the following websites: Copaxone Autoject/Autoject 2 [23] , Extavia Auto-injector/Auto-injector II [24] , Rebif Rebiject/Rebiject II [25] . Note: the RebiSmart autoinjector was not included as it has not been approved for use in the US. Pen injector devices such as the Rebif Rebidose were also excluded as they are not autoinjectors (Table S1 ) and asked to rate how well the BETACONNECT autoinjector performed across these attributes, rating from 1
(not well at all) to 10 (very well). Patients compared their current autoinjector with BETACONNECT, agreeing or disagreeing with a number of statements by assigning a rating from 1 (strongly disagree) to 10 (strongly agree; 
RESULTS
Demographic Characteristics
A total of 90 respondents with MS agreed to participate, and completed the survey (Table 1) . Ideal Autoinjector Attributes Figure 2 shows the most important features of an ideal autoinjector according to the percentage of patients who assigned a high score of 8, 9, or 10 (top three scores on a 10-point scale) for each attribute. The most highly valued attributes were: the injection process is easy overall (96%), easy to push the button to start the injection (88%), and autoinjector is comfortable to hold during injections (86%). Other features that were rated highly included the ability to use the autoinjector without help from others (83%), adjustable injection depth (81%), and being able to reach different injection sites (78%).
Patients were also asked to assign the maximum rating of 10 to only one of the attributes. The ideal autoinjector attribute
given the most number of maximum scores was the injection process is easy overall (26%), with the ability to use the autoinjector without help from others and the sound of injection is minimal (quiet) both gaining the next highest number of maximum scores (11% each). Built-in dwell time (i.e., the time the needle remains in the skin after the medication has been injected) was most valued (97%), followed by the self-check feature (84%), greater ability to customize injections (84%) and adjustment of injection speed (83%). The subsequent assessment of overall autoinjector preference revealed that 83% of patients preferred BETACONNECT to their current autoinjector, as they agreed with the statement ''I would rather use the new autoinjector than my current autoinjector'' (Fig. 5) . The main reasons for the preference for BETACONNECT were ease of injection, user-friendly functions such as built-in dwell time and automatic needle retraction, and quiet injections. Preference was also analyzed by patient age group (Table 2) , showing a high (100%) preference for BETACONNECT in younger patients (i.e., 18-40 years of age), with older patients slightly less likely to switch. on being easy to use, comfortable to hold, customization for optimal comfort during injections, and being able to self-inject without help and so maintain independence.
Comparison of Current Autoinjector With
These results are in broad agreement with previous published results. For example, a survey of patients with MS showed that the main reason for not self-injecting was physical difficulty in performing the injections (57%) [15] . Another survey showed that major concerns preventing self-injection were fear of performing injections properly and ability to access various injection sites (both 47%) [16] . A decline in fine motor skills is a common problem among patients with MS, reducing their ability to administer injections [4] . Thus, improvements in autoinjector ease of use are vital to allow patients to fulfill their desire to maintain their independence by performing self-injections.
It is interesting to note that while some of the features of BETACONNECT were not thought to be of major importance among the ideal autoinjector attributes (e.g., adjustable injection speed), they were rated more highly once patients had performed simulated injections with BETACONNECT.
This may be because patients were not aware what features were potentially feasible as they Fig. 2 Ideal autoinjector attributes rating from 1 to 10 (where 10 is most important and 1 least important). The percentages represent the proportion of patients who selected a rating of 8, 9 or 10 for each attribute had not encountered them at this stage of the survey. Another example of this phenomenon was quietness of injection, which was overall rated rather low among the initial assessment of ideal autoinjector attributes as assessed by the percentage giving a score of 8, 9, or 10, even though it was the second most desirable attribute according to the number of maximum scores. The results reveal an interesting dichotomy: prior to encountering BETACONNECT patients thought quiet injections were either not an important attribute or regarded it as major issue. After patients had experienced quiet simulated injections using BETACONNECT many changed their opinions, as 63% of patients thought that lack of a loud noise upon injection would reduce their anxiety (Fig. 4) .
While BETACONNECT outperformed
Copaxone Autoject or Autoject 2 and Rebif Rebiject or Rebiject II over all of the autoinjector attributes, this outperformance was particularly marked in features that were not highly rated in the initial assessment of Fig. 3 BETACONNECT, Autoject and Rebiject, compared individually against an ideal autoinjector across 18 attributes. Attribute ratings for an ideal autoinjector are also shown (green bars). Autoject, Rebiject and BETA-CONNECT were rated based on how well they performed across the attributes, from 1 (not well) to 10 (very well). For each attribute, the percentage of patients who selected a rating of 8, 9, or 10 for each autoinjector using symbols as shown in the legend. Note: we did not compare Extavia patients separately vs. other groups because there were only two patients using Extavia. The other groups had enough patients for us to analyze and compare them. The two patients using Extavia autoinjectors were included in the total number of 90 patients (all patients following the demonstration and simulated injections with BETACONNECT) attributes prior to performing simulated injections with the new autoinjector (e.g., injection reminders, audible cues, quietness of injection, ability to adjust injection speed, and knowing when to remove the needle). This strongly suggests that the improvements in autoinjector design featured in BETACONNECT may be meeting the patients' needs, even needs that they were unaware of before using it. It is worth noting here that we were unable to include the RebiSmart autoinjector in the survey as it has not been approved for use in the US.
The main reasons for the preference for BETACONNECT in the current survey appear to be the ease of injection (e.g., minimal pressure needed to press the injection button, helping patients to reach various injection sites across the body); user-friendly features such as built-in dwell time and automatic needle retraction; visible/audible cues denoting when the injection is complete to prevent premature needle withdrawal; and the quiet nature of the injection. Likewise, the minority who preferred to use their current autoinjector tended to be older, more concerned about potential Requires less assistance 40%
Increases independence 43%
Will be able to use more injection sites 51%
May improve adherence to medication 58%
Quiet injections will reduce anxiety 63%
More comfortable to handle 63%
Better look and feel 67% 79%
69%
Customizing speed/depth may reduce pain 69%
Reminder reduces chance of forgetting injections 71%
More comfortable injections 74%
Injection process is easier 78%
Lights/button make operation self-explanatory 83% Injection sound is more user-friendly 83% Automatic needle retraction is valuable Adjusting injection speed may increase comfort 83%
Greater ability to customize injections 84% Self-check feature will improve reliability 84%
Built-in dwell time ensures full drug delivery 97%
Less anxiety with new autoinjector n = 90 Fig. 4 Attitudes and perceptions towards BETACON-NECT in comparison with patients' current autoinjectors, showing the percentage who scored statements 8, 9, or 10 (where 1 is strongly disagree and 10 is strongly agree). The percentages represent the proportion of patients who selected a rating of 8, 9, or 10 for each statement electronic malfunctions, preferred their 'less bulky' current device, or were just used to their current autoinjector and unwilling to change.
The BETACONNECT attributes valued by most patients were knowing when to pull the needle out after an injection (99%), adjustable injection speed (99%), visual cues to show injection progress (98%), being able to use without help (98%), easy to push a button to start injections (97%), and being easy to tell when an injection starts and stops (97%; Fig. 3 ). In addition, the new autoinjector features valued by patients over their current auto injector were the built-in dwell time (97%), self-check function (84%), injection speed adjustment (83%), low injection noise (83%), and automatic needle retraction (83%; Fig. 4 ).
Considering these results together, they reflect the key features of BETACONNECT that make it particularly useful for patients with MS, notably automatic needle insertion and retraction, audio/visual cues that indicate the injection progress and the successful end of an injection, and adjustable injection speed and depth to allow customized injection settings. Automatic needle insertion, dwell time, and retraction, in conjunction with visual and audible signals, ensure that injections are delivered completely.
This meets common concerns that the injection might not be performed correctly [16] ; many patients in the current survey said they counted to ten when using their mechanical as one survey showed that 34% of patients did not use their injection device as they wanted to control their injections, including control of the speed and depth of needle insertion [16] . BETACONNECT also features a unique injection reminder function. While only 71% of patients thought that the reminder function might be helpful ( Fig. 4) , this feature may become more important with use, as forgetting to take medications for MS is the most common reason for non-adherence to MS drug therapy, owing to the cognitive changes that form part of the natural disease course [17, 18] . [19] . Betaseron patients were excluded as patient satisfaction surveys with patients using BETACONNECT were conducted previously [13, 14] . The current survey does not contain adherence data, so we cannot know for sure that BETACONNECT will increase adherence to DMTs. Clearly, adherence
to DMTs is of great importance as it may reduce the incidence of relapses, lead to fewer hospitalizations and avoid excess use of healthcare resources [4] . Other studies have shown promising adherence rates with other electronic autoinjectors used by patients with MS [20, 21] . Several BETACONNECT studies to investigate adherence are on-going or are planned to start shortly to investigate this issue.
CONCLUSIONS
Adherence to DMTs is vital to optimize treatment efficacy and so improve patient outcomes, but it nevertheless remains a challenge [4, 22] . Ongoing improvements in autoinjector design and functionality as exemplified by BETACONNECT may allow patients with MS to overcome many self-injection difficulties that can, for example, result in poor adherence to MS drug therapy. In the current survey, BETACONNECT attributes and features were rated highly by patients, compared with both an ideal autoinjector and their current mechanical autoinjector. As such, these findings suggest that the use of BETACONNECT may increase patient satisfaction and potentially increase overall medication adherence. 
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